|
Market Closed -
Nasdaq
16:00:00 2026-09-15 EDT
|
5-day change | 1st Jan Change | ||
| 216.17 USD | -0.55% |
|
+1.73% | +22.83% |
| 09-14 | Biogen Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 09:15 AM | |
| 09-11 | Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11) | RE |
Company Valuation: Biogen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 35,242 | 39,877 | 37,495 | 22,283 | 25,818 | 31,940 | - | - |
| Change | - | 13.15% | -5.97% | -40.57% | 15.86% | 23.71% | - | - |
| Enterprise Value (EV) 1 | 37,820 | 40,560 | 43,384 | 26,204 | 28,289 | 36,877 | 34,360 | 31,288 |
| Change | - | 7.24% | 6.96% | -39.6% | 7.96% | 30.36% | -6.82% | -8.94% |
| P/E | 23.1x | 13.3x | 32.5x | 13.7x | 20x | 37.3x | 19.4x | 15.7x |
| PBR | 3.26x | 3.02x | 2.53x | 1.33x | 1.42x | 1.73x | 1.57x | 1.42x |
| PEG | - | 0x | -0.5x | 0.3x | -0.9x | -1.1x | 0.2x | 0.7x |
| Capitalization / Revenue | 3.21x | 3.92x | 3.81x | 2.3x | 2.61x | 3.06x | 3x | 2.92x |
| EV / Revenue | 3.44x | 3.99x | 4.41x | 2.71x | 2.86x | 3.53x | 3.22x | 2.86x |
| EV / EBITDA | 9.13x | 11.2x | 14.3x | 7.1x | 7.82x | 13.5x | 9.93x | 8.56x |
| EV / EBIT | 10.3x | 13.1x | 17x | 8.69x | 9.97x | 14.7x | 10.7x | 8.91x |
| EV / FCF | 11.2x | 35.5x | 34.2x | 9.63x | 13.8x | 19.6x | 13.7x | 11x |
| FCF Yield | 8.94% | 2.82% | 2.93% | 10.4% | 7.25% | 5.1% | 7.32% | 9.12% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 10.4 | 20.87 | 7.97 | 11.18 | 8.79 | 5.792 | 11.16 | 13.75 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10,982 | 10,173 | 9,836 | 9,676 | 9,891 | 10,444 | 10,656 | 10,951 |
| EBITDA 1 | 4,144 | 3,618 | 3,040 | 3,689 | 3,618 | 2,740 | 3,461 | 3,656 |
| EBIT 1 | 3,656 | 3,099 | 2,545 | 3,015 | 2,838 | 2,513 | 3,208 | 3,511 |
| Net income 1 | 1,556 | 3,047 | 1,161 | 1,632 | 1,293 | 963.8 | 1,855 | 2,187 |
| Net Debt 1 | 2,578 | 683 | 5,888 | 3,921 | 2,471 | 4,937 | 2,420 | -652.2 |
| Reference price 2 | 239.92 | 276.92 | 258.77 | 152.92 | 175.99 | 216.17 | 216.17 | 216.17 |
| Nbr of stocks (in thousands) | 146,893 | 144,001 | 144,898 | 145,719 | 146,702 | 147,754 | - | - |
| Announcement Date | 2/3/22 | 2/15/23 | 2/13/24 | 2/12/25 | 2/6/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 37.53x | 3.55x | 13.52x | -.--% | 32.12B | |
| 18.38x | 4.26x | 10.01x | 0.49% | 79.26B | |
| 20.07x | 4.29x | 13.32x | 2.45% | 58.62B | |
| -17.5x | 26.14x | -16.97x | -.--% | 58.56B | |
| 34.59x | 11.77x | 22.57x | -.--% | 48.75B | |
| 21.02x | 4.65x | 13.25x | 0.69% | 46.32B | |
| 54.53x | 3.46x | 26.78x | -.--% | 24.77B | |
| 63.72x | 6.81x | 40.43x | -.--% | 21.5B | |
| 23.49x | 5.04x | 13.12x | -.--% | 15.97B | |
| -26.81x | 14.88x | -40.13x | -.--% | 14.15B | |
| Average | 22.90x | 8.48x | 9.59x | 0.36% | 40B | |
| Weighted average by Cap. | 20.47x | 8.86x | 9.76x | 0.54% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BIIB Stock
- Valuation Biogen Inc.
Select your edition
All financial news and data tailored to specific country editions
